Search Results - "Dugan, U"

From adaptive licensing to adaptive pathways: Delivering a flexible life-span approach to bring new drugs to patients by Eichler, H-G, Baird, LG, Barker, R, Bloechl-Daum, B, Børlum-Kristensen, F, Brown, J, Chua, R, Del Signore, S, Dugan, U, Ferguson, J, Garner, S, Goettsch, W, Haigh, J, Honig, P, Hoos, A, Huckle, P, Kondo, T, Le Cam, Y, Leufkens, H, Lim, R, Longson, C, Lumpkin, M, Maraganore, J, O'Rourke, B, Oye, K, Pezalla, E, Pignatti, F, Raine, J, Rasi, G, Salmonson, T, Samaha, D, Schneeweiss, S, Siviero, PD, Skinner, M, Teagarden, JR, Tominaga, T, Trusheim, MR, Tunis, S, Unger, TF, Vamvakas, S, Hirsch, G

“…The concept of adaptive licensing (AL) has met with considerable interest. Yet some remain skeptical about its feasibility. Others argue that the focus and…”
Get full text

2012 POSTER Activity of capecitabine (C) and docetaxel (D) doublets with and without trastuzumab (T) in a breast cancer xenograft model by Moisa, C, Kolinsky, K, Zhang, Y.E, Dugan, U, Packman, K, Higgins, B

Get full text

2060 POSTER An open-label study of neoadjuvant capecitabine (C) and docetaxel (D) with/without trastuzumab (T) to determine the role of p53 mutations in clinical and pathological responses in patients with recently diagnosed breast cancer (BC) by Nancy, P, Truong, S, Tripathy, D, Glück, S, Dugan, U, Wu, L

Get full text

Abstract P4-06-07: Activity of nivolumab alone or in combination with targeted therapies in a humanized BLT-mouse model of human breast cancer by O'Brien, NA, Luo, T, Ayala, R, Salgar, S, Conklin, D, McDermott, M, Kitchen, S, Rezek, V, Horak, C, Dugan, U, Slamon, DJ

“…Abstract Background: Recent advances in the field of cancer immunotherapy have increased demand for reliable preclinical models to inform patient selection and…”
Get full text

A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: a phase II study by Traina, TA, Theodoulou, M, Dugan, U, Feigin, K, Patil, S, Geneus, S, Godfrey, L, Norton, L, Hudis, C

“…Abstract Abstract #6121 Background
 Capecitabine (Xeloda®,C) has activity in breast cancer when dosed for 14 days (d) followed by a 7d rest (14 - 7). Using…”
Get full text

Use of an alternative preclinical regimen of capecitabine (C) to enhance single agent and combination activity in a colorectal cancer xenograft model by Kolinsky, K. D., Chen, J., Zhang, Y., Andria, M., Dugan, U., Heimbrook, D., Packman, K., Higgins, B.

“…Abstract only…”
Get full text

A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: A phase II study by Traina, T. A., Theodoulou, M., Dugan, U., Feigin, K., Patil, S., Edwards, C., Norton, L., Hudis, C. A.

“…Abstract only…”
Get full text

Preclinical activity of combinations of capecitabine (C), docetaxel (D), and trastuzumab (T) in a breast cancer xenograft model by Kolinsky, K., Zhang, Y., Moisa, C., Dugan, U., Packman, K., Higgins, B.

“…Abstract only 13508 Background: C is highly active, well tolerated, and extends survival when added to D in pretreated metastatic BC. We report preclinical…”
Get full text

Phase I study of a novel capecitabine schedule based on Norton-Simon mathematical modeling by Theodoulou, M., Traina, T. A., Dugan, U., Lake, D., Fornier, M., Feigin, K., Patil, S., Edwards, C., Norton, L., Hudis, C. A.

“…Abstract only 1045 Background: We have previously described a mathematical method to optimize chemotherapy dose and schedule (Norton et al, AACR 2005)…”
Get full text

Preclinical testing of a novel regimen of capecitabine (C) in combination with bevacizumab (B) and trastuzumab (T) in a breast cancer xenograft model by Traina, T. A., Higgins, B., Theodoulou, M., Dugan, U., Kolinsky, K., Zhang, Y., Heimbrook, D., Packman, K., Hudis, C., Norton, L.

“…Abstract only 1049 Background: Mathematical methods applied to xenograft breast cancer models have determined that the maximum impact of C therapy occurs after…”
Get full text

Utilization and costs of supportive medications among patients with metastatic breast (mBC) or colorectal cancer (mCRC) by Dugan, U., Baran, R. W., Barron, J., Law, A. W., Waugh, W. J., Grochulski, W. D., Cummins, G.

“…Abstract only…”
Get full text

Utilization and costs of supportive medications among patients with metastatic breast (mBC) or colorectal cancer (mCRC) by Dugan, U., Baran, R. W., Barron, J., Law, A. W., Waugh, W. J., Grochulski, W. D., Cummins, G.

“…Abstract only…”
Get full text